The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to an Nrf2-activator for use in identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the Nrf2-activator is administered to a subject, wherein the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and wherein an ASD phenotype 1 patient is identified by a negative response.

The present invention is directed to a pharmaceutical composition comprising an Nrf2-inhibitor. Likewise, the present invention is directed to a pharmaceutical composition for use in the treatment of ASD in a patient, comprising: determining whether the patient suffers from ASD subtype 1 and administering a therapeutically effective amount of an Nrf2-inhibitor if the patients suffers from ASD subtype 1, wherein determining whether the patient suffers from ASD subtype 1 comprises administering the patient an Nrf2-activator and identifying the patient as suffering from ASD subtype 1 if he shows a negative response.

Compositions comprising a fluorescein component and benoxinate component and the corresponding uses of these compositions are described herein. These compositions have improved storage life and the fluorescein component and/or benoxinate component minimally degrade after 12 to 18 months of storage.

Provided herein are hypoxia inducible factor 2-alpha (HIF-2α)-specific radioactive tracers, methods of use thereof, and methods of synthesis thereof. Specifically, provided herein are HIF-2α-specific radioactive tracers comprising an HIF-2α-specific agent developed as a therapeutic inhibitor and a positron emitting radioactive label. Embodiments provide methods of detecting an HIF-2α-expressing tumor, detecting an HIF-2α inhibitor resistant tumor, evaluating a change in HIF-2α expression in response to an anti-cancer treatment, detecting acquisition of HIF-2α inhibitor resistance, evaluating efficacy of an HIF-2α depletion therapy, detecting or monitoring an ischemic area in a subject, or detecting and monitoring pulmonary hypertension in a subject. Also provided are methods of synthesizing an HIF-2α-specific radioactive tracer.

Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.

The present disclosure relates to compositions and methods for enhancing mosquito feeding.

Incorporation of deuterium into the lipids, proteins, and/or genetic material in cells, tissues, organs, or organisms, including animals, such as humans, and plants, by administration of heavy water, allows for the spectral determination of levels of lipids, proteins, and/or genetic material using Raman spectroscopy, such as stimulated Raman spectroscopy. Following administration of a drug, changes in the relative amounts of lipid, protein, and/or genetic materials can be determined, and the efficacy, or lack thereof, of the administered drug can be determined.

A system and method for screening cervical cancer is disclosed. The system and method enable screening of cervical cancer locally at geographical location of subjects using minimum infrastructure. The system includes a visual inspection kit, a device, and a subject connection module. The visual inspection kit may include a vital stain having a predefined concentration, a sterile accessory, and an applicator accessory. The device may include an application for data collection, storage, transmission, retrieval and analytics and the subject connection module is configured to manage interaction with subjects. The method includes screening a subject using the visual inspection kit, storing and analyzing the images using the device, and connecting with subject using the subject connection module.

The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.